Solid Biosciences (SLDB) Prices 21.74M Share Common Offering at $5.75/Sh

Solid Biosciences Inc., (NASDAQ: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Solid has granted the underwriters a 30-day option to purchase up to an additional 3,260,869 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Solid. The offering is expected to close on March 23, 2021, subject to customary closing conditions.

The Company expects to use net proceeds from this offering to fund research and development expenses, including the advancement of SGT-001, and for working capital and other general corporate purposes.

Jefferies, SVB Leerink and Piper Sandler are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.

The shares are being offered pursuant to an effective shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on March 13, 2019, and declared effective by the SEC on March 19, 2019.

This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

You May Also Be Interested In

• Enliven Therapeutics prices upsized public offering at $37.50 per share
• AES prices $1 billion senior notes offering with 2029 and 2033 maturities
• Healthcare Triangle raises $3.6 million through convertible note offering